News

Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FDA approval was based on data from

This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), demonstrated

AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of

With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareholders secured for each share, 1.00 share of BMS common stock

Sarizotan was granted the orphan drug designation from the FDA for the treatment of the rare neurodevelopmental disorder. Rett syndrome is known to affect mainly females and currently

TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD). Sangamo expects to open the first clinical sites

CNS’ licensing agreement with HPI grants the Company the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer globally. In its agreement

Daratumumab is a first-in-class biologic designed to target CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage. Daratumumab is considered to

In this regard, the companies will make use of GalXC, an RNA interference (RNAi) technology platform developed by Dicerna, for the discovery of new therapies. The collaboration will